Ketamine’s Neuroprotection in Parkinson’s Models: BDNF Independence

Sub-Anesthetic Ketamine Confers Neuroprotection in Parkinson’s Models

Sub-anesthetic doses of ketamine (20 mg/kg, intraperitoneal) provide robust neuroprotective effects in a progressive rodent model of Parkinson’s disease (PD), according to a preclinical study published on October 29, 2026 (OpenAlex W7224354381). The research team administered ketamine prior to striatal injection of the neurotoxin 6-hydroxydopamine (6-OHDA), a well-established method for inducing parkinsonian degeneration in rats. Behavioral assessments revealed near-complete protection against the development of parkinsonian motor deficits in ketamine-treated animals, despite only modest preservation of striatal dopaminergic markers. This finding adds to a growing body of literature suggesting that low-dose ketamine may have therapeutic potential in neurodegenerative conditions beyond its established psychiatric uses.

Neuroprotection Occurs Independently of BDNF-TrkB Signaling

The neuroprotective effects of ketamine in this model do not depend on the brain-derived neurotrophic factor (BDNF) signaling pathway, as evidenced by experiments involving the TrkB antagonist ANA-12. The research group previously reported that ketamine’s reduction of L-DOPA-induced dyskinesia (LID) in similar models was mediated by BDNF signaling. However, in this progressive PD model, co-administration of ANA-12 did not block ketamine’s neuroprotective effects, nor did it significantly alter striatal tyrosine hydroxylase (TH) content or substantia nigra neuron counts. In situ hybridization showed no significant changes in BDNF expression, and while TrkB receptor expression decreased with ANA-12 co-administration, this did not impact the observed motor protection. This divergence from expected neurotrophic mechanisms highlights the complexity of ketamine’s actions in the brain and suggests that other molecular pathways may be responsible for its neuroprotective profile in neurodegenerative disease models.

Implications for Translational Research and Policy

These findings have important implications for the design of future translational and clinical studies of ketamine in Parkinson’s disease and related disorders. The demonstration that ketamine’s neuroprotection is BDNF-independent suggests that relying solely on neurotrophic endpoints may miss clinically relevant effects. Researchers designing early-phase clinical trials (e.g., Phase 1/2a) may need to broaden biomarker panels to include alternative mechanisms, such as anti-inflammatory, glutamatergic, or mitochondrial pathways. Policy makers and regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), may also need to consider these mechanistic nuances when evaluating investigational new drug (IND) applications for ketamine or related compounds in neurodegenerative indications. Notably, the study’s use of a progressive, rather than acute, PD model provides a more translationally relevant context, as most human PD cases are slowly progressive. This choice underscores the importance of model selection in preclinical research and highlights a potential failure mode: overreliance on acute models may overestimate neuroprotective efficacy in clinical populations.

Risks, Unknowns, and Limitations

While sub-anesthetic ketamine demonstrated behavioral neuroprotection, the underlying mechanisms remain unclear, and the disconnect between motor improvement and dopaminergic neuron preservation raises questions about functional versus structural endpoints. High-dose ketamine is known to be neurotoxic, and the safety window for chronic or repeated low-dose administration in humans with neurodegenerative disease is not established. Furthermore, rodent models, even progressive ones, do not fully recapitulate the complexity of human PD, and translation to clinical efficacy remains uncertain. The study also highlights that behavioral improvements can occur without full preservation of dopaminergic markers, suggesting compensatory or circuit-level adaptations that may not be durable or generalizable. Finally, the potential for off-target effects or interactions with other neurobiological systems warrants careful monitoring in future studies.

Looking Ahead: Alternative Mechanisms and Clinical Translation

The discovery that ketamine’s neuroprotective effects in PD models are BDNF-independent opens new avenues for mechanistic research and therapeutic development. Future studies should systematically investigate alternative pathways, such as modulation of glutamate transmission, anti-inflammatory effects, or synaptic plasticity mechanisms distinct from BDNF-TrkB signaling. Clinical trial sponsors may consider adaptive designs that allow for mechanistic biomarker discovery alongside efficacy endpoints. For stakeholders across neuroscience, clinical research, and policy, this study exemplifies the need for flexible, mechanism-agnostic approaches when repurposing established drugs for complex neurodegenerative conditions. As research progresses, a deeper understanding of ketamine’s multifaceted neurobiology will be critical to realizing its potential—while rigorously assessing safety and translational validity.

By Dr. Alex R. Mendel, PhD (Neuropharmacology). Reviewed by Dr. Lisa Tran, MD, on 2026-10-31. Research based on primary preclinical data and direct source analysis.